Molecular profiling approaches for identifying novel biomarkers

Expert Opinion on Drug Safety

Volumn 3, Issue 2, 2004, Pages 137-151

  Bailey, Wendy J ^a   Ulrich, Roger ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b ROSETTA INPHARMATICS   (United States)

Author keywords

Biomaker; Microarray; Molecular profiling; Toxicogenomics; Transcriptional fingerprint

Indexed keywords

ADIPSIN; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; CISPLATIN; CLOFIBRATE; GAMMA SECRETASE INHIBITOR; GEMFIBROZIL; HEXOBARBITAL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PHENOBARBITAL; PHTHALIC ACID BIS(2 ETHYLHEXYL) ESTER; RECEPTOR BLOCKING AGENT; TOXIN; TRANSPLATIN; XENOBIOTIC AGENT;

ANALYTIC METHOD; CLINICAL STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DNA FINGERPRINTING; DNA MICROARRAY; DRUG RESEARCH; DRUG RESPONSE; DRUG SCREENING; DRUG UPTAKE; EXPERIMENTATION; GENE TECHNOLOGY; GENETIC PROCEDURES; GENETIC TRANSCRIPTION; HUMAN; MATHEMATICAL COMPUTING; MAXIMUM TOLERATED DOSE; METABOLISM; MOLECULAR INTERACTION; MONITORING; NONHUMAN; OUTCOMES RESEARCH; PATHOLOGY; PREDICTION; PROTEOMICS; REVIEW; STATISTICAL SIGNIFICANCE; STRUCTURE ACTIVITY RELATION; TOXICITY; DRUG DESIGN; DRUG EFFECT; GENE EXPRESSION PROFILING; GENETIC POLYMORPHISM;

BIOLOGICAL MARKERS; DRUG DESIGN; GENE EXPRESSION PROFILING; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, GENETIC; TRANSCRIPTION, GENETIC; XENOBIOTICS;

EID: 2342540427     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.3.2.137     Document Type: Review

References (65)

1. PETRICOIN EF III, HACKETT JL, LESKO LJ et al.: Medical applications of microarray technologies: a regulatory science perspective. Nat. Genet. Suppl. (2002) 32:474-479.
2. IDEKER T, GALITSKI T, HOOD L: A new approach to decoding life: systems biology. Annu. Rev. Genomics Hum. Genet. (2001) 2:343-372.
3. BIOMARKERS DEFINITIONS WORKING GROUP: Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. (2001) 69:89-95.
4. THE FOOD AND DRUG MODERNIZATION ACT OF 1997: Title 21 Code of Federal Regulations. Part 314, Subpart H, Section 314.500.
5. COLBURN WA. Biomarkers in drug discovery and development: from target identification through drug marketing. J. Clin. Pharmacol. (2003) 43(4):329-341.
6. SCHADT EE, MONKS SA, FRIEND SH: A new paradigm for drug discovery: integrating clinical, genetic, genomic and molecular phenotype data to identify drug targets. Biochem. Soc. Trans. (2003) 31(2):437-443.
7. FRANK R, HARGREAVES R. Clinical biomarkers in drug discovery and development. Nat. Rev. Drug Discov. (2003) 2(7):566-580.
8. MORRISH PK, RAKSHI JS, BAILEY DL, SAWLE GV, BROOKS DJ: Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J. Neurol. Neurosurg. Psychiatry (1998) 64(3):314-319.
9. DU AT, SCHUFF N, ZHU XP et al.: Atrophy rates of entorhinal cortex in AD and normal aging. Neurology (2003) 60(3):481-486.
10. WAGNER JA: Overview of biomarkers and surrogate endpoints in drug development. Dis. Markers (2002) 18(2):41-46.
11. WARING JF, DAI X, HE Y, LUM P, ROBERTS CJ, ULRICH R.'If you build it, they will come': design, construction and use of a compendium of expression profiles for mechanism of toxicity prediction. In: Toxicogenomics: Principles and Applications. Hamadeh HK, Afshari CA (Eds), Wiley Publishers, NY. In Press.
12. WARING JF, ULRICH RG: The impact of genomics-based technologies on drug safety evaluation. Annu. Rev. Pharmacol. Toxicol. (2000) 40:335-352.
13. CASTLE AL, CARVER MP, MENDRICK DL: Toxicogenomics: a new revolution in drug safety. Drug Discov. Today (2002) 7(13):728-736.
14. ULRICH R, FRIEND SH: Toxicogenomics and drug discovery: will new technologies help us produce better drugs? Nat. Rev. Drug Discov. (2002) 1(1):84-88.
15. GERHOLD DL, JENSEN RV, GULLANS SR. Better therapeutics through microarrays. Nat. Genet. Suppl. (2002) 32:547-552.
16. TUGWOOD JD, HOLLINS LE, COCKERILL MJ: Genomics and the search for novel biomarkers in toxicology. Biomarkers (2003) 8:79-92.
17. SISTARE FD: Development and application of interspecies biomarkers in nonclinical safety evaluations. In: Biomarkers in Clinical Drug Development. Bloom JC, Dean RA (Eds), Marcel Dekker, Inc., NY (2003):97-117.
18. MACGREGOR JT: The future of regulatory toxicology: impact of the biotechnology revolution. Toxicol. Sci. (2003) 75:236-248.
19. MORRIS AJ: Information and observer disagreement in histopathology, Histopathology (1994) 25:123-128.
20. BOORMAN GA, HASEMAN JK, WATERS MD, HARDISTY JF, SILLS RC: Quality review procedures necessary for rodent pathology databases and toxicogenomic studies: the National Toxicology Program Experience. Toxicol. Pathol. (2002) 30:88-92.
21. FURNESS PN: The use of digital images in pathology. J. Pathol. (1997) 183:253-263.
22. KRIETE A, ANDERSON MK, LOVE B et al.: Combined histomorphometric and gene-expression profiling applied to toxicology. Genome Biol. (2003) 4(5):R32.
23. PANDURO A, SHALABY F, WEINER FR, BIEMPICA L, ZERN MA, SHAFRITZ DA: Transcriptional switch from albumin to α-fetoprotein and changes in transcription of other genes during carbon tetrachloride induced liver regeneration. Biochemistry (1986) 25(6):1414-1420.
24. CLARKE H, EGAN DA, HEFFERNAN M et al.: α-glutathione s-transferase (α-GST) release, an early indicator of carbon tetrachloride hepatotoxicity in the rat. Hum. Exp. Toxicol. (1997) 16(3):154-157.
25. ROLAN P, ATKINSON AJ, LESKO LJ: Use of biomarkers from drug discovery through clinical practice: report of the Ninth European Federation of Pharmaceutical Sciences Conference on Optimizing Drug Development. Clin. Pharmacol. Ther. (2003) 73:284-291.
26. NUWAYSIR EF, BITTNER M, TRENT J, BARRETT JC, AFSHARI CA: Microarrays and toxicology: the advent of toxicogenomics. Mol. Carcinog. (1999) 24(3):153-159.
27. OSCARSON M: Pharmacogenetics of drug metabolizing enzymes: importance for personalized medicine. Clin. Chem. Lab. Med. (2003) 41(4):573-580.
28. ROGERS JF, NAFZIGER AN, BERTINO JS Jr: Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am. J. Med. (2002) 113(9):746-750.
29. LIOTTA L, PETRICOIN E: Molecular profiling of human cancer. Nat. Rev. Genet. (2000) 1:48-56.
30. DEPRIMO SE, WONG LM, KHATRY DB: Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification. BMC Cancer (2003) 3(1):3.
31. ALIZADEH AA, EISEN MB, DAVIS RE et al.: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (2000) 403:503-511.
32. VAN'T VEER LJ, DAI H, VAN DE VIJVER MJ et al.: Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 415(6871):530-536.
33. VAN DE VIJVER MJ, HE YD, VAN'T VEER LJ et al.: A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. (2002) 347:1999-2009.
34. BUCKHAULTS P, ZHANG Z, CHEN YC et al.: Identifying tumor origin using a gene expression-based classification map. Cancer Res. (2003) 63:4144-4149.
35. RADMACHER MD, MCSHANE LM, SIMON R: A paradigm for class prediction using gene expression profiles. J. Comput. Biol. (2002) 9(3):505-511.
36. THOMAS RS, RANK DR, PENN SG et al.: Identification of toxicologically predictive gene sets using cDNA microarrays. Mol. Pharmacol. (2001) 60(6):1189-1194.
37. DENISON MS, WHITLOCK JP Jr: Xenobiotic-inducible transcription of cytochrome P450 genes. J. Biol. Chem. (1995) 270(31):18175-18178.
38. HAMADEH HK, BUSHEL PR, JAYADEV S et al.: Gene expression analysis reveals chemical-specific profiles. Toxicol. Sci. (2002) 67(2):219-231.
39. HAMADEH HK, BUSHEL PR, JAYADEV S et al.: Prediction of compound signature using high density gene expression profiling. Toxicol. Sci. (2002) 67(2):232-240.
40. WARING JF, CIURLIONIS R, JOLLY RA, HEINDEL M, ULRICH RG: Microarray analysis of hepatotoxins in vitro reveals a correlation between gene expression profiles and mechanisms of toxicity. Toxicol. Lett. (2001) 120(1-3):3059-368.
41. WARING JF, JOLLY RA, CIURLIONIS R et al.: Clustering of hepatotoxins based on mechanism of toxicity using gene expression profiles. Toxicol. Appl. Pharmacol. (2001) 175(1):28-42.
42. HUANG Q, DUNN RT II, JAYADEV S et al.: Assessment of cisplatin-induced nephrotoxicity by microarray technology. Toxicol. Sci. (2001) 63(2):196-207.
43. BAN M, HETTICH D, HUGUET N: Nephrotoxicity mechanism of cis-platinum (II) diamine dichloride in mice. Toxicol. Lett. (1994) 71(2):161-168.
44. SAFIRSTEIN R, MILLER P, GUTTENPLAN JB: Uptake and metabolism of cisplatin by rat kidney. Kidney Int. (1984) 25(5):753-758.
45. BURCZYNSKI ME, MCMILLIAN M, CIERVO J et al.: Toxicogenomics-based discrimination of toxic mechanism in HepG2 human hepatoma cells. Toxicol. Sci. (2000) 58(2):399-415.
46. ABRAHAM SC, WU TT. KLIMSTRA DS et al.: Distinctive molecular genetic alterations in sporadic and familial adenomatouspolyposis-associated pancreatoblastomas: frequent alterations in the APC/β-catenin pathway and chromosome 11p. Am. J. Pathol. (2001) 159(5):1619-1627.
47. DESMAZE C, SORIA JC, FREULET-MARRIERE MA, MATHIEU N, SARATIER L: Telomere-driven genomic instability in cancer cells. Cancer Lett. (2003) 194(2):173-182.
48. GILES RH, VAN ES JH, CLEVERS H: Caught up in a Wnt storm: Wnt signaling in cancer. Biochim. Biophys. Acta (2003) 1653(1):1-24.
49. BIGNOLD LP: Initiation of genetic instability and tumour formation: a review and hypothesis of a nongenotoxic mechanism. Cell. Mol. Life Sci. (2003) 60(6):1107-1117.
50. ROGERS LK, MOORTHY B, SMITH CV: Acetaminophen binds to mouse hepatic and renal DNA at human therapeutic doses. Chem. Res. Toxicol. (1997) 10(4):470-476.
51. JAESCHKE H, KNIGHT TR, BAJT ML: The role of oxidant stress and reactive nitrogen species in acetaminophen hepatotoxicity. Toxicol. Lett. (2003) 144(3):279-288.
52. MYTILINEOU C, KRAMER BC, YABUT JA. Glutathione depletion and oxidative stress. Parkinsonism Relat. Disord. (2002) 8(6):385-387.
53. SEARFOSS GH, JORDAN WH, CALLIGARO DO et al.: Adipsin: a biomarker of gastrointestinal toxicity mediated by a functional γ-secretase inhibitor. J. Biol. Chem. (2003) 278:46107-46116..
54. BUTTE A: The use and analysis of microarray data. Nat. Rev. Drug Discov. (2002) 1(12):951-960.
55. SIMON R, RADMACHER MD, DOBBIN K, MCSHANE LM: Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J. Natl. Cancer Inst. (2003) 95(1):14-18.
56. DUDOIT S, FRIDLYAND J, SPEED TP: Comparison of discrimination methods for the classification of tumours using gene expression data. J. Am. Stat. Assoc. (2002) 97:77-87.
57. DING CH: Unsupervised feature selection via two-way ordering in gene expression analysis. Bioinformatics (2003) 19(10):1259-1266.
58. JORNSTEN R, YU B: Simultaneous gene clustering and subset selection for sample classification via MDL. Bioinformatics (2003) 19(9):1100-1109.
59. KLUGER Y, BASRI R, CHANG JT, GERSTEIN M: Spectral biclustering of microarray data: coclustering genes and conditions. Genome Res. (2003) 13(4):703-716.
60. BURA E, PFEIFFER RM: Graphical methods for class prediction using dimension reduction techniques on DNA microarray data. Bioinformatics (2003) 19(10):1252-1258.
61. GOLUB TR, SLONIM DK, TAMAYO P et al.: Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science (1999) 286(5439):531-537.
62. ALBRECHT A, VINTERBO SA, OHNO-MACHADO L: An Epicurean learning approach to gene-expression data classification. Artif. Intell. Med. (2003) 28(1):75-87.
63. LI W, YANG Y: Zipf's law in importance of genes for cancer classification using microarray data. J. Theor. Biol. (2002) 219(4):539-551.
64. PEDDADA SD, LOBENHOFER EK, LI L, AFSHARI CA, WEINBERG CR, UMBACH DM: Gene selection and clustering for time-course and dose-response microarray experiments using order-restricted inference. Bioinformatics (2003) 19(7):834-841.
65. BRAZMA A, HINGAMP P, QUACKENBUSH J et al.: Minimum information about a microarray experiment (MIAME) - toward standards for microarray data. Nat. Genet. (2001) 29(4):365-371.